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Primary cutaneous B cell lymphomas represent a
distinct group of lymphoproliferative disorders that
can be distinguished from systemic lymphoma by
their good response to local treatment and favorable
prognosis. In systemic B cell lymphoma, inactivation
of p15INK4b and p16INK4a is frequently observed and
may be associated with a poor prognosis. There have
been no comprehensive studies in primary cutaneous
B cell lymphomas, however. Mechanisms of p15/p16
inactivation include loss of heterozygosity, homo-
zygous deletion, promotor region hypermethylation,
and point mutation. We analyzed DNA from 36
cases of primary cutaneous B cell lymphomas, four
systemic B cell lymphomas, and six benign B cell
lymphoproliferative in®ltrates for abnormalities of
p15 and p16 using microsatellite markers for 9p21,
methylation speci®c polymerase chain reaction, and
polymerase chain reaction/single stranded conforma-
tional polymorphism analysis with exon speci®c
primers. Expression of both p15 and p16 protein
was assessed by immunohistochemistry. Loss of
heterozygosity at 9p21 was identi®ed in 2 out of
36 primary cutaneous B cell lymphomas. Hyper-
methylation of p15 and p16 promotor regions was
identi®ed in 8 of 35 (23%) and 15 of 35 (43%) cases,
respectively. In two cases p16 hypermethylation was
identi®ed in recurrent disease but not in the initial
tumor. No point mutations were identi®ed. In seven
patients, however, a polymorphism was observed in
exon 3 of the p16 gene. In primary cutaneous B cell
lymphomas with allelic loss or promotor hyper-
methylation of either p15 or p16, loss of expression
in tumor cells was identi®ed in 5 of 8 and 9 of 10
cases, respectively. Our ®ndings suggest that
p15INK4b and p16INK4a biallelic gene abnormalities
are common in primary cutaneous B cell lympho-
mas, most frequently as a result of promotor hyper-
methylation. The presence of abnormalities in
recurrent disease in some cases suggests that inacti-
vation of p15 and p16 may be involved in disease
progression. Key words: chromosome 9/loss of hetero-
zygosity/promotor hypermethylation. J Invest Dermatol
118:941±948, 2002
P
rimary cutaneous B cell lymphomas (PCBCL) represent
a heterogeneous group of diseases with different clinical,
histologic, and immunophenotypic features and may be
either indolent or aggressive. Speci®c chromosomal
abnormalities are characteristic of different systemic
lymphomas but attempts to identify tumor-speci®c chromosomal
abnormalities in PCBCL have been disappointing. The t(14; 18)
translocation is found in the majority of nodal follicular
lymphomas, leading to upregulation of the bcl-2 gene, which
prevents apoptosis (Weiss et al, 1987). This translocation is not
usually found in PCBCL even in those with histologic features
suggestive of a follicle center cell origin (Cerroni et al, 1994;
Grùnbñk et al, 2000; Child et al, 2001a; Franco et al, 2001).
Most malignancies accumulate a series of genetic abnormalities
including inactivation of different tumor suppressor genes. Biallelic
gene inactivation may be a consequence of different mechanisms
including loss of chromosomal material [loss of heterozygosity
(LOH) or homozygous deletion], intragenic mutation, and/or
hypermethylation of CpG islands within the promotor leading to
transcriptional silencing (Jones and Laird, 1999).
The tumor suppressor genes p15INK4b and p16INK4b are located
on chromosome 9p21 and encode cyclin-dependent kinase
inhibitors (negative cell cycle regulators) (Serrano et al, 1993;
Kamb et al, 1994). Both proteins bind to cyclin-dependent kinases
4 and 6 (CDK4, CDK6) and inhibit the kinase activity of the
cyclin-kinase complexes, producing functional inactivation of the
retinoblastoma protein and the subsequent block of the G1 phase of
the cell cycle.
Loss of cell cycle control is a common alteration in neoplasia
(Hirama and Koef¯er, 1995), leading to uncontrolled cell growth.
Inactivation of both p15 and p16 by homozygous deletions,
mutation, and hypermethylation occurs in a wide range of human
tumors, and has been identi®ed in systemic B cell lymphoma
(Dreyling et al, 1995; Gombart et al, 1995; Herman et al, 1997;
Elenitoba-Johnson et al, 1998; Baur et al, 1999). p15 and p16 gene
inactivation is associated with aggressive tumors and may play a role
in progression of indolent disease (Herman et al, 1997; Elenitoba-
Johnson et al, 1998; Pinyol et al, 1998; Villuendas et al, 1998).
We have analyzed 36 PCBCL and four cases of systemic
lymphoma with cutaneous lesions for inactivation of both p15 and
p16 genes by various mechanisms including LOH, promotor
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hypermethylation, and point mutation. We have correlated these
data with immunohistochemical evidence of p15 and p16 expres-
sion and the histologic subtype and grade of tumor.
MATERIALS AND METHODS
Frozen tissue samples from 36 cases of PCBCL, four systemic follicular
lymphomas with cutaneous lesions, and six benign cutaneous B cell
in®ltrates were retrieved. In three cases of PCBCL, recurrent lesions
were also available for analysis. The corresponding histologic and
immunohistochemistry sections had been reviewed and classi®ed accord-
ing to the World Health Organization Classi®cation of Tumors of
Haematopoietic and Lymphoid Tissues (Harris, 2001). Cases included
eight follicle center cell lymphoma (FCCL), 19 marginal zone lymphoma
(MZL), eight diffuse large cell lymphoma (DLCL), and one unclassi®able
case.
All cases of PCBCL studied had either a dominant clonal immuno-
globulin heavy chain gene (IgH) rearrangement in lesional skin, identi-
®ed using polymerase chain reaction (PCR) methodology (Child et al,
2001b), or immunohistochemical evidence of light chain restriction. For
each case, a corresponding polyclonal control sample was also obtained.
Tumor cells made up > 50% of the in®ltrate in 22 cases and > 75% in
eight cases (all DLCL). In six cases a B cell clone was identi®ed by gene
analysis but the admixture of in¯ammatory cells made up > 50% of the
in®ltrate.
DNA extraction DNA was extracted from freshly obtained or frozen
tissue specimens according to standard procedures using proteinase K
digestion and phenol/chloroform extraction. For promotor hyper-
methylation analysis, a control DNA sample was extracted from the Raji
cell line (ECCAC No: 85011429) (derived from a case of Burkitt's
lymphoma, which is methylated at the promotor CpG islands of both
p16INK4a and p15INK4b).
Analysis of allelic loss on 9p21 DNA from both lesional skin and
normal tissue in each case was analyzed for LOH by PCR ampli®cation
of the following highly polymorphic dinucleotide repeat sequences:
D9S126, IFNA (a marker located within the interferon-a locus
¯anking the p15 and p16 genes), intra p15/p16 (a dinucleotide
repeat located between the p15INK4b and p16INK4a genes), and a
further marker, D9S171, also ¯anking the p15 and p16 genes (Amersham
Pharmacia Biotech, Little Chalfont, U.K.) (Heyman et al, 1996). The
reaction mix (20 ml ®nal volume) consisted of 0.2±0.5 mg of template
DNA, 1 3 PCR buffer (Amersham Pharmacia Biotech), 200 mmol per
liter [a33P] deoxycytidine triphosphate, 200 mmol per liter each of the
other deoxyribonucleoside triphosphates, 0.1% Tween, 100 ng synthetic
oligonucleotide primers (Amersham Pharmacia Biotech), and 1 unit of
taq (thermus aquaticus) polymerase (Amersham Pharmacia Biotech) in
combination with taq antibody (Clontech, Basingstoke, U.K.).
The presence of homozygous deletions was also assessed in all cases by
a comparative multiplex PCR assay (Cairns et al, 1994) using a primer
set (D13S160) from outside the area of 9p21 and a primer set for the
locus of suspected homozygous deletion on 9p21 (D9S1747 and
D9S1748).
PCR was performed using a Perkin Elmer thermal cycler (Model
9700, Perkin Elmer, Warrington, U.K.). The annealing temperatures
used were as follows: D9S126, IFNA, and D9S171, D9S1747, D9S1748,
55°C; intra p15/p16, 50°C. The PCR were performed over 25±30
cycles.
P15INK4b and p16INK4a promotor region hypermethylation The
methylation status of the p15 and p16 gene promoters was analyzed
using bisul®te modi®cation. Methylation speci®c PCR was carried out as
described by Herman et al (1996). In this technique, DNA is chemically
modi®ed by sodium bisul®te, which changes the unmethylated but not
the methylated cytosines into uracil. The bisul®te-treated DNA is
subjected to PCR ampli®cation using primers designed to anneal
speci®cally to the methylated and unmethylated bisul®te-modi®ed DNA
within a given gene. A PCR product is obtained when the sequence
covered by the primers is methylated. Brie¯y, 1 mg genomic DNA was
denatured in 0.2 mol per liter NaOH (Sigma-Aldrich, Poole, U.K.)
(volume 50 ml) for 20 min at 37°C. After the addition of 550 ml of a
freshly prepared solution containing 10 mmol per liter hydroquinone
(Sigma-Aldrich) and 3 mol per liter sodium bisul®te (Sigma-Aldrich)
(pH 5.2), the samples were incubated overnight (16±21 h) at 55°C. The
bisul®te-modi®ed DNA was puri®ed on Qiaquick DNA puri®cation
columns (Qiagen, Crawley, U.K.) according to the manufacturer's
speci®cations and eluted with 50 ml of water. The DNA was treated
with 50 ml of 0.6 mol per liter NaOH for 20 min at room temperature,
precipitated by ethanol at ±70°C, and resuspended in 20 ml of water.
Bisul®te-modi®ed DNA was ampli®ed by PCR using primer sets speci®c
for the methylated and unmethylated p15 (p15 M and U) and p16 (p16
M and M2, U and U2) sequences (Herman et al, 1996). Prior to
chemical modi®cation, PCR with wild-type (W) primers were also
performed using nonbisul®te-modi®ed DNA to ensure adequate DNA
quality. Because tumor cells are always admixed with reactive cells in
lymphomas, the PCR ampli®cations using primers speci®c for
unmethylated DNA were considered as positive controls for the
ef®ciency of chemical modi®cation. The reaction mix (50 ml ®nal
volume) consisted of 1 mg of template DNA, 1 3 PCR buffer
(Amersham Pharmacia Biotech), 200 mmol per liter [a33P] deoxycytidine
triphosphate, 200 mmol per liter each of the other deoxyribonucleoside
triphosphates, 2.5 mmol per liter MgCl2, 0.1% Tween, 100 ng synthetic
oligonucleotide primers (Amersham Pharmacia Biotech), and 1 unit of
taq (thermus aquaticus) polymerase (Amersham Pharmacia Biotech) in
combination with taq antibody (Clontech). The annealing temperatures
used were as follows: p16 M and M2, 65°C; p16 U and U2, 60°C; p15
M and U, 60°C. The PCR were performed over 30±35 cycles.
Point mutations and small deletions Genomic DNA was subjected
to PCR ampli®cation using primers for exons 1±3 of the p16 gene and
exons 1±2 of the p15 gene (Heyman et al, 1996). The reaction mix was
similar to that used for LOH analysis, but ampli®cation of p16 exons 2
and 3 and p15 exon 2 required additional MgCl2 at a concentration of
2.5 mmol per liter. The annealing temperatures used were as follows:
p16 exon 1, 57°C; p16 exon 2 and 3, 60°C; p15 exon 1, 55°C; p15
exon 2, 60°C. All PCR were performed over 35 cycles.
Analysis of ampli®cation products
LOH analysis and promotor hypermethylation An aliquot of the radiolabeled
PCR products was run on a denaturing polyacrylamide gel [6%
acrylamide (Gibco BRL, Paisley, U.K.), 7 mol per liter urea (United
States Biochemicals, Cleveland, OH)]. The gel was run at 30 W for 2±
4 h, depending on the size of the PCR product, at room temperature in
0.5 3 TBE buffer. For LOH analysis, each sample was run in a pair
with a corresponding normal control sample from each patient. For
promotor hypermethylation, the ampli®cation products using the
methylated and unmethylated primers were run next to each other for
each patient with the Raji cell line as a positive control.
Comparative multiplex PCR An aliquot of the PCR products was run
on a 2% agarose gel. A homozygous deletion would be indicated when
the D9S1747 or D9S1748 signal was signi®cantly less than the signal
from the D13S160 (control) allele (as assessed with densitometry).
Point mutations/small deletions Radiolabeled products were separated by
single stranded conformational polymorphism (SSCP) analysis
polyacrylamide gel (with 10% glycerol) electrophoresis run at 30 W for 8
h at 4°C.
Gels were transferred to a sheet of 3 mm Whatman paper and vacuum
dried at 80°C. Autoradiography was carried out at room temperature for
24±72 h with an intensifying screen.
Sequence analysis Products obtained from promotor hyper-
methylation of the Raji cell line and similar products obtained from cases
of PCBCL were sequenced to con®rm identi®cation of the correct
product. Abnormal bands obtained from PCR/SSCP analysis were also
sequenced to identify mutations/deletions.
Bands were excised from the gels and re-ampli®ed using a biotinylated
5¢ methylation speci®c or 5¢ exon speci®c primer together with the
appropriate 3¢ primer. Successful re-ampli®cation was determined by
electrophoresis on 2% agarose gels and the PCR products were passed
through microspin columns (Amersham Pharmacia Biotech) to remove
unincorporated primers. The ampli®cation products were immobilized
on the surface of streptavidin-coated microbeads (Dynabeads M-280,
Dynal, Oslo, Norway) to produce single-stranded PCR products. The
chain termination DNA sequencing method was performed using the
Sequenase Version 2.0 DNA sequencing kit (United States
Biochemicals). Products were analyzed by denaturing polyacrylamide gel
electrophoresis and visualized by autoradiography.
Immunohistochemical analysis for p15 and p16
expression Paraf®n-embedded histologic skin sections corresponding
to the DNA samples in 31 cases of PCBCL, three cases of systemic FCL,
and ®ve cases of reactive lymphoid hyperplasia were identi®ed and
stained for both p15 (Laboratory Vision, Newmarket, U.K.) and p16
(Santa Cruz Biotechnology, Santa Cruz) expression using mouse
monoclonal antibodies. Both p15 and p16 are nuclear proteins and
nuclear staining of cells by the antibody was considered as a positive
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signal for protein expression. Sections were dewaxed, incubated in 0.01
M sodium citrate, and microwaved for 18 min. The antibodies were
diluted, applied to the sections for 30 min, and detected using the
indirect streptavidin technique. The ®nal reaction products were
developed with 3¢-3¢¢ diaminobenzidine. Sections from reactive lymph
nodes were used as controls for normal expression of p15 and p16.
Sections were examined by a histopathologist (EC) without prior
knowledge of the results obtained from the molecular studies. The
percentage of tumor cells with nuclear staining of p15/p16 was recorded
as follows: +++, 75%±100% of tumor cells positive; ++, 50%±75% of
tumor cells positive; +, 25%±50% of tumor cells positive; +±, < 25% of
tumor cells positive.
Correlation with clinical features (summarized in
Table I) Adequate follow-up data were available for 34 of the 36 cases
of PCBCL investigated. Clinical data collected included age of onset and
length of follow-up; site of lesions and whether they were solitary or
multiple; number of cutaneous recurrences and those with ongoing
disease. In relevant cases, extracutaneous spread and date of death were
also recorded.
Overall, 19 males and 17 females were affected. The median age at
onset of disease was 54 y (range 12±93 y). The median age of onset in
the cases of DLCL was 76 y (range 22±93 y). In the 34 cases with
follow-up data the median length of follow-up was 51 mo (range 12±
193 mo). The most common site of presentation was the scalp in cases
of FCCL, the trunk in MZL, and the lower leg in cases of DLCL.
Eleven patients presented with multifocal lesions. Cutaneous recurrence
was frequent following treatment and six patients subsequently developed
lymph node involvement (four of these cases had DLCL). Three of these
six patients have died of their disease (all with DLCL). A further patient
with DLCL developed bone marrow involvement and also died. The
majority of patients were treated with radiotherapy, three patients were
treated with single agent chemotherapy (chlorambucil), and six were
given multiagent chemotherapy with CHOP (cyclophosphamide, adria-
mycin, vincristine, prednisolone) (®ve of these cases had developed
lymph node disease). Two patients with DLCL that had failed to respond
to CHOP were treated with rituximab, which produced a short
remission; one patient has died and the other received an autologous
peripheral blood stem cell transplant, leading to a remission of 18 mo,
but this patient has subsequently developed recurrent cutaneous disease.
RESULTS (SUMMARIZED IN TABLE II)
LOH LOH was identi®ed in 2 of 36 (6%) cases of PCBCL. In
one case (DLCL) loss was identi®ed with the intragenic p15/p16
marker (intra p15/16) but not with the ¯anking markers (Fig 1).
In the second case (MZL) loss occurred at one ¯anking marker
(IFNA) but was identi®ed only in DNA extracted from a second
biopsy at disease recurrence.
No samples demonstrated LOH at both markers ¯anking either
the p15 (p15/p16 and D9S171) or p16 (p15/16 and IFNA) genes,
suggesting the absence of homozygous deletions. Larger homo-
zygous deletions affecting both the p15 and the p16 gene could be
missed using this method alone, but comparative multiplex PCR
also failed to identify large homozygous deletions.
Promotor hypermethylation Promotor hypermethylation at
p15 was identi®ed in 8 of 35 (23%) cases of PCBCL overall,
consisting of 1 of 8 (12.5%) FCCL, 6 of 18 (33%) MZL, and 1 of 8
(12.5%) DLCL (Fig 2a).
Promotor hypermethylation at p16 was identi®ed in 15 out of 35
(43%) cases of PCBCL overall, consisting of 3 of 8 (37.5%) FCCL,
7 of 18 (39%) MZL, 4 of 8 (50%) DLCL, and the one unclassi®able
case (Fig 2b).
It was also identi®ed in two of four cases of systemic FCL. In two
cases of PCBCL, p16 hypermethylation was identi®ed only in
DNA from biopsies taken at disease recurrence but not in the
original biopsies.
Hypermethylation of both p15 and p16 promotors was identi®ed
in 4 of 35 (11%) cases (one FCCL, two MZL, one DLCL).
Sequence analysis of methylated and unmethylated p15 and p16
products obtained from the Raji cell line and selected cases
con®rmed ampli®cation of the correct product.
Of the six benign B cell lymphoproliferative in®ltrates that were
analyzed, all ampli®ed using the primers speci®c for unmethylated
DNA but none showed promotor hypermethylation at either the
p15 or p16 promotor.
In one case the bisul®te-modi®ed DNA failed to amplify with
primers speci®c for both methylated and umethylated p15 and p16
promotors suggesting that modi®cation had failed.
Combined LOH and promotor hypermethylation, suggesting a
biallelic event, was not identi®ed in any case, although biallelic
promotor hypermethylation cannot be excluded.
PCR/SSCP analysis for point mutations and small
deletions Identical band shifts were identi®ed in seven cases
when PCR products were analyzed following ampli®cation of
exon 3 of the p16 gene (Fig 3a).
Sequence analysis identi®ed a C®T transition at nucleotide
position 580, which is a previously described polymorphism in the
untranslated region of exon 3 (Holland et al, 1995) (Fig 3b).
No point mutations or small deletions were identi®ed in either
the p15 or p16 gene.
Correlation with p15 and p16 expression (see Table II) p15
expression by tumor cells in all eight cases of PCBCL with p15
promotor hypermethylation was examined (cases 3, 10, 11, 13,
17±19, 30). Five of eight cases showed decreased expression by
tumor cells (positive nuclear staining of only 50%±75% of tumor
cells in three cases and 25%±50% in two cases). Of 15 cases of
PCBCL with p16 promotor hypermethylation, paraf®n-embedded
material corresponding to the extracted DNA was available for
analysis in only 10 cases (cases 1, 3, 9, 11, 13, 26, 28, 30, 31, 34).
Nine of ten demonstrated reduced expression of p16 by tumor cells
(< 25% tumor cells expressed p16 in one case, 25%±50% tumor
cells expressed p16 in four cases, and between 50% and 75% tumor
cells expressed p16 in four cases). In cases 1 and 34, where p16
hypermethylation had been identi®ed in recurrent disease only,
absent p16 expression was identi®ed only in histologic sections
from recurrent disease but not in the original biopsy material. In
case 35, in which LOH between p15 and p16 genes but no other
genetic abnormality had been identi®ed, fewer than 50% of the
tumor cells expressed p15 and fewer than 25% expressed p16.
Of the 15 cases with no molecular evidence of gene inactivation,
immunohistochemistry was performed in 14 cases. Ten cases
showed expression of p15 and p16 by all tumor cells. In the other
four cases, one showed absent expression of p15, and three showed
absent expression of p16 by a subpopulation of tumor cells.
Figure 1. Results of LOH analysis. Polyacrylamide gel electrophoresis
of tumor (T) and control (N) DNA PCR products in one case with
LOH using primers intra p15/p16. Arrow indicates loss of an allele
(> 50% reduction of band intensity). Additional bands in both tumor
and control samples are present due to DNA slippage, which is more
readily apparent when using 33PdCTP than with 32PdCTP radiolabeled
products.
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In PCBCL, particularly cases of MZL, the tumor population is
often relatively small compared with the surrounding in®ltrate of
reactive cells. In six cases of MZL (cases 10, 11, 14, 16, 18, and 19)
the percentage of tumor cells in the in®ltrate was less than 50% of
the total cell population [as assessed by histology and immunohis-
tochemistry and the intensity (using densitometry) of the clonal B
cell population by PCR analysis of the immunoglobulin heavy
chain gene]. Absent expression of p15 (case 14) and p16 (case 16) in
a subpopulation of tumor cells with no detectable molecular
abnormalities could occur because the tumor population is too
small for the abnormalities to be identi®ed using the techniques
employed.
In the two cases of systemic lymphoma with p16 hypermethyla-
tion, absent expression of p16 occurred in between 50% and 75% of
tumor cells.
Normal expression of both p15 and p16 in mononuclear cells
was seen in the ®ve cases of reactive lymphoid hyperplasia
examined.
In all cases, p15 and p16 staining of basal keratinocytes within the
epidermis was identi®ed and acted as a positive internal control
(Fig 4a, b, c).
Correlation with clinical features (see Table I) Overall, cases
of PCBCL with promotor hypermethylation/LOH had had their
disease for a shorter period (median 46 mo) than those without
detectable abnormalities (median 70 mo). p15/p16 gene
abnormalities were no more frequent in cases with multiple
compared with solitary lesions and did not correlate with site of
disease or rates of cutaneous recurrence. Six patients subsequently
developed lymph node involvement; promotor hypermethylation
was identi®ed in three of these patients (all with DLCL). Allelic loss
at 9p21 was identi®ed in a further patient with DLCL who remains
well following treatment (follow-up 2 y).
The two cases of systemic FCCL with p16 hypermethylation are
alive with ongoing, indolent disease.
DISCUSSION
The results from this study suggest that p15 and p16 gene
abnormalities at 9p21 are common in PCBCL. Abnormalities were
identi®ed in 61% of cases studied and most frequently occurred as a
result of promotor hypermethylation (55%), affecting the p16 gene
more often than the p15 gene (43% compared to 23%). In the
majority of cases with p15 or p16 gene abnormalities it was possible
to demonstrate reduced expression of either p15 or p16 protein by
tumor cells, which suggests biallelic hypermethylation leading to
gene inactivation. In contrast, the small number of cases in which
there was normal p15 and p16 protein expression in the context of
hypermethylation may be explained by involvement of only one
allele.
Figure 3. PCR/SSCP and sequence analysis of p16INK4a exon 3.
(A) PCR/SSCP analysis of p16INK4a exon 3. An identical band shift can
be seen in lanes 2, 3, and 12. (B) Sequence analysis of the aberrant band
identi®ed a C®T base change at position 580 in the 3¢ untranslated
region of the p16 gene. A: Sequence obtained from a case with a normal
pattern on SSCP analysis. B: Sequence obtained from a case with a band
shift. Arrow indicates C®T base change.
Figure 2. Methylation speci®c PCR of bisul®te-modi®ed DNA.
(A) Using primer pairs speci®c for methylated and unmethylated
p15INK4b promotor sequences in each case. M, primers speci®c for
methylated DNA; U, primers speci®c for unmethylated DNA. 1 is DNA
from Raji cell line (positive control) showing ampli®cation with the
primer pair speci®c for methylated DNA. 5 and 7 illustrate p15
hypermethylation in two cases of PCBCL (a product is also obtained
with the primers speci®c for unmethylated DNA because of
ampli®cation of DNA from normal reactive cells present in the initial
biopsy specimen). 2±4 and 6 show ampli®cation with primers speci®c for
unmethylated DNA only. The two bands obtained in the methylated
lanes represent denatured methylated single DNA strands, con®rmed by
sequence analysis of both products. (B) Using primer pairs speci®c for
methylated and unmethylated p16INK4a promotor sequences in each case.
M, primers speci®c for methylated DNA; U, primers speci®c for
unmethylated DNA. 1, negative control (no DNA); 2, DNA from Raji
cell line (positive control) showing ampli®cation with the primer
sequences speci®c for methylated DNA but not with those speci®c for
unmethylated DNA. 8 illustrates p16 promotor hypermethylation in one
case of PCBCL (a product is also obtained with the primers speci®c for
unmethylated DNA because of ampli®cation of DNA from normal
reactive cells present in the initial biopsy specimen). 3±7, 9, and 10 show
ampli®cation with primers speci®c for unmethylated DNA only. The
two bands obtained in the methylated lanes represent denatured
methylated single DNA strands, con®rmed by sequence analysis of both
products.
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High rates of hypermethylation, affecting both the p15 and p16
promotor regions, have been identi®ed in systemic B cell non-
Hodgkins lymphoma. In a study by Herman et al (1997),
hypermethylation of p16INK4a, often without alterations of
p15INK4b, was seen commonly in NHL and was more frequent
in cases with high-grade histology. By contrast, Baur et al (1999)
identi®ed p15 hypermethylation in 64% (55% low-grade, 78%
high-grade) and p16 hypermethylation in 32% (low-grade 21%,
high-grade 50%) of nodal forms of NHL. Although our data
indicate that p15 and p16 hypermethylation occur commonly, p16
hypermethylation is more frequent, particularly in DLCL, and in
the cases of systemic NHL that we studied, only p16 hypermethy-
lation was identi®ed. Both p15 and p16 hypermethylation was
found in 11% of our cases and was equally distributed between
different subtypes.
LOH was an infrequent ®nding and homozygous deletions were
not identi®ed in any case examined. We cannot fully exclude false
negative results, however, because, in PCBCL, tumor cells are
often accompanied by a signi®cant in®ltrate of reactive cells, which
can lead to failure to identify LOH in tissue samples. Ampli®cation
of DNA extracted from microdissected tumor cells may identify
further cases with allelic loss, as has previously been identi®ed in
primary cutaneous CD30-positive large cell lymphoma (BoÈni et al,
2000).
Both cases with LOH at 9p21 had high-grade features on
histology, in which the majority of cells were neoplastic. LOH
implies that one allele of either gene has been deleted, leaving the
second allele still functional. Expression of p15 and p16 was normal
in one case, but in the case with LOH at the intragenic p15/16
marker, expression of both p15 and p16 by the tumor cells was less
than 50% and 25%, respectively. These ®ndings suggest inactivation
of the second allele by an alternative mechanism, but in this case no
other genetic abnormality was identi®ed by our techniques.
In systemic B cell lymphoma, homozygous deletions at 9p21 are
found in only a small proportion of cases and appear to be
associated with progression of low-grade follicle center lymphoma
to DLCL but not with de novo high-grade DLCL (Elenitoba-
Johnson et al, 1998). In our series, three cases of recurrent disease
were studied, and in one case of MZL allelic loss was only
identi®ed in DNA from a recurrent lesion, which histologically
showed high-grade features; however, no homozygous deletions
were identi®ed. In hematologic malignancies homozygous dele-
tions that extend over 500 kb and encompass both p15 and p16
genes and the interferon gene cluster are common (Dreyling et al,
1995) and would not be detected using our LOH technique.
Comparative multiplex PCR (Cairns et al, 1994), however, also
failed to detect any homozygous deletions. Southern blot analysis
(Ogawa et al, 1994) would have helped to identify larger
homozygous deletions in our cases.
No point mutations or small deletions were identi®ed, other
than a previously recognized polymorphism at position 580 in the
3¢ untranslated region of p16 exon 3 (Holland et al, 1995) in seven
cases. These results are consistent with other studies in NHL
(Pinyol et al, 1998; Villuendas et al, 1998) and suggest that in
contrast to other solid organ malignancies such as melanoma
(Holland et al, 1999) mutations are not an important mechanism of
p15/p16 gene inactivation. SSCP/PCR analysis only detects
mutations that result in an abnormal electrophoretic pattern,
however, and therefore it is possible that other mutations may have
been missed.
Studies of p15 and p16 genes in cutaneous T cell lymphoma
(CTCL) have also been performed recently. Peris et al (1999)
showed lack of p16 expression in 25% of cases of mycosis
fungoides, but found no association with point mutations or
minor deletions of the p16 gene. Other studies have subse-
quently identi®ed promotor hypermethylation, leading to gene
inactivation. Scarisbrick et al (2002) showed that hypermethyla-
tion in CTCL most commonly involves the p15 promotor
rather than the p16 promotor. Other studies have shown p16
hypermethylation more commonly in tumor stage mycosis
fungoides (Navas et al, 2000), however, suggesting that p16
inactivation is involved in progression of disease. In our study,
p16 promotor hypermethylation was more frequent in DLCL,
and was identi®ed in three of four patients with DLCL who
developed lymph node involvement. p15/p16 gene inactivation
was also identi®ed in recurrent but not presenting lesions in
Figure 4.Immunohistochemical evidence of reduced expression
of p15 and p16 protein by the neoplastic cells. (a) Section from a
low-grade MZL with p15 hypermethylation demonstrating expression of
p15 by < 50% of tumor cells. Nuclear staining of basal keratinocytes acts
as a positive internal control (original magni®cation 310). (b) Section
from a high-grade DLCL with p16 hypermethylation demonstrating
absent expression of p16 protein (original magni®cation 340). (c) Section
from a DLCL with LOH identi®ed at intra p15/p16 showing that
<25% of the large tumor cells express p16 (original magni®cation 3100).
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three patients, which suggests that inactivation of the p15 and
p16 genes may play a role in disease progression.
In our study, loss of expression of p15 and p16 by tumor cells
was identi®ed in 63% and 90% of cases with detectable gene
abnormalities, respectively. The admixed in®ltrate of reactive
lymphocytes and the dif®culties in identifying malignant from
reactive cells, particularly in low-grade PCBCL, may explain why
absent protein expression was not seen in all lymphocytes within
the in®ltrates. Alternatively, gene inactivation may be restricted to a
subpopulation of tumor cells.
In cases with no detectable gene abnormalities, normal expres-
sion of p15 and p16 by tumor cells was identi®ed in the majority of
cases studied. Reduced expression of either p15 (one case) or p16
(three cases) by tumor cells, however, may be due to either failure
to identify genetic inactivation by the molecular techniques
employed (false negatives) or failure of the immunohistochemical
technique, although this is unlikely as positive nuclear staining of
basal keratinocytes within the biopsy specimen acted as a positive
internal control.
Epigenetic phenomena such as aberrant methylation of genes
involved in tumor suppression, cell cycle regulation, apoptosis,
DNA repair, and metastatic potential have now been identi®ed in
many malignancies. Each human cancer has a unique pro®le of
promotor hypermethylation in which some genetic changes are
shared and others are cancer type speci®c. These ®ndings will help
to outline the disruption of critical pathways in tumorigenesis and
to derive sensitive molecular detection strategies for different
tumors. Promotor hypermethylation of p73 (a tumor suppressor
gene), MGMT (a DNA repair gene), and DAPK (a gene related to
metastasis and invasion) have been discovered at high frequencies in
systemic lymphoma (Estella et al, 2001). Analysis of the promotor
regions of these genes in PCBCL may help to identify cases with a
poor prognosis.
In summary, we have identi®ed frequent inactivation of p15 and
p16 genes in PCBCL, most commonly as a result of promotor
hypermethylation. Inactivation of p16 is more common and occurs
at similar frequencies in both low- and high-grade disease.
Identi®cation of p15/p16 gene abnormalities in recurrent disease
suggests a role in disease progression. Investigation of other
candidate genes is required.
Fiona J. Child was supported by grants from the Special Trustees of Guy's Hospital
and Dermatrust.
Table I. Clinical details of patients with PCBCL
Case Disease type Sex
Age at
onset Original site Recurrence
Length of
disease Extracutaneous spread Treatment
1 FCCL F 53 Scalp 3 3 46 mo ± Radiotherapy
2 FCCL M 66 Scalp 3 3 84 mo ± Radiotherapy
3 FCCL F 78 Scalp Nil 54 mo ± Radiotherapy
4 FCCL M 76 Scalp Nil Lost to F/U ± Radiotherapy
5 FCCL F 28 Scalp Nil 72 mo ± Radiotherapy, CHOP
6 FCCL F 31 Multifocal Ongoing 18 mo ± Nil
7 FCCL M 46 Trunk Nil 15 mo ± Radiotherapy
8 FCCL M 47 Scalp Nil 18 mo ± Radiotherapy
9 MZL M 51 Scalp Nil 32 mo ± Radiotherapy
10 MZL F 74 Multifocal (trunk) Ongoing 36 mo ± Declined treatment
11 MZL F 60 Multifocal
(face, trunk)
Ongoing 60 mo ± Radiotherapy
12 MZL M 63 Face, trunk Multiple 138 mo Lymph nodes
(at 108 mo)
Radiotherapy, CHOP
13 MZL M 54 Face, trunk Multiple 78 mo ± Radiotherapy
14 MZL M 46 Trunk 3 2 84 mo ± Radiotherapy
15 MZL M 45 Trunk 3 2 69 mo Lymph node Radiotherapy, CHOP
16 MZL F 61 Upper limbs Nil 60 mo ± Radiotherapy
17 MZL M 33 Scalp 3 1 24 mo ± Excision, radiotherapy
18 MZL F 64 Trunk Ongoing 120 mo ± Radiotherapy, chlorambucil
19 MZL M 42 Multifocal (trunk) Ongoing 193 mo ± Radiotherapy, s/c interferon-a
20 MZL M 41 Trunk Multiple 78 mo ± Radiotherapy
21 MZL F 59 Arm, forehead Nil 48 mo ± Radiotherapy
22 MZL M 28 Trunk Ongoing 126 mo ± OHchloroquine
23 MZL F 58 Upper limbs Nil 36 mo ± Excision
24 MZL F 70 Face Nil 24 mo ± Radiotherapy
25 MZL M 27 Multifocal Ongoing 150 mo ± Radiotherapy
26 MZL M 35 Multifocal Ongoing 55 mo ± Radiotherapy
27 MZL M 12 Trunk, arm 3 1 88 mo ± Radiotherapy
28 Unclassi®able M 40 Trunk Lost to F/U Lost to F/U Lost to F/U Lost to F/U
29 DLCL F 22 Upper and
lower limbs
Multiple 138 mo Lymph node (60 mo) Radiotherapy, rituximab,
CHOP, APBSCT
30 DLCL F 90 Lower leg Nil 18 mo ± Radiotherapy
31 DLCL F 77 Lower leg 3 2 30 mo Lymph node (12 mo) Radiotherapy (skin and LN)
32 DLCL M 75 Lower leg Multiple 24 mo Bone marrow,
died of disease
Radiotherapy, chlorambucil
33 DLCL F 93 Lower leg Nil 18 mo ± Radiotherapy
34 DLCL M 73 Lower leg Multiple
(multifocal)
42 mo Lymph nodes,
died of disease
Radiotherapy, chlorambucil,
rituximab, CHOP,
interferon-a
35 DLCL F 54 Scalp Nil 24 mo ± Radiotherapy
36 DLCL F 79 Scalp Multiple 12 mo Lymph node,
died of disease
Radiotherapy, CHOP
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